

**510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY**

A. 510(k) Number:

k100716

B. Purpose for Submission:

Clearance of a new device

C. Measurand:

D-dimer

D. Type of Test:

Quantitative

E. Applicant:

Aalto Scientific, Ltd.

F. Proprietary and Established Names:

AuditTM MicroCVTM D-Dimer Linearity Set

G. Regulatory Information:

1. Regulation section:
21 CFR 864.5425
2. Classification:
Class II
3. Product code:
GGN-Plasma, Coagulation Control
4. Panel:
81 (Hematology)

H. Intended Use:

1. Intended use(s):
The AuditTM MicroCVTM D-Dimer Linearity Set is a quantitative, assayed quality control material consisting of five levels of D-dimer analyte. The five D-dimer levels demonstrate a linear relationship to each other for D-dimer analyte. The AuditTM MicroCVTM D-Dimer Linearity Set is intended to use with the Biomerieux miniVIDAS[®] analyzer and VIDAS[®] D-dimer assay to verify the calibration of the measuring range. AuditTM MicroCVTM D-Dimer Linearity Set is “For *In Vitro* Diagnostic Use Only.”
2. Indication(s) for use:
Same as intended use(s)
3. Special conditions for use statement(s):
For prescription use only
4. Special instrument requirements:
Biomerieux miniVIDAS[®] analyzer and VIDAS[®] D-dimer assay

I. Device Description:

The AuditTM MicroCVTM D-Dimer Linearity Set is a human based, lyophilized, five level set of QC material, A, B, C, D, and E. Each level contains D-dimer complex. It is used to confirm the proper calibration of the measuring range of D-dimer on the miniVIDAS[®] analyzer. Level A D-dimer is near the lower limit level and level E D-dimer is near the upper limit of the measuring range. Levels B, C, and D are related by linear dilution of level A and level E. The target ranges for five levels are:

Levels	A	B	C	D	E
Target Range	<150 ng/mL	1105-1495 ng/mL	2010-2760 ng/mL	2145-4255 ng/mL	3700-6000 ng/mL

J. Substantial Equivalence Information:

1. Predicate device name(s):
Triage® D-dimer Calibration Verification Controls
2. Predicate K number(s):
k050799
3. Comparison with predicate:

Similarities		
Item	Device: Audit™ MicroCV™ D-Dimer Linearity Set	Predicate: Triage® D-dimer Calibration Verification Controls
Intended Use	The Audit™ MicroCV™ D-Dimer Linearity Set is a quantitative, assayed quality control material consisting of five levels of D-dimer analyte. The five D-dimer levels demonstrate a linear relationship to each other for D-dimer analyte. The Audit™ MicroCV™ D-Dimer Linearity Set is intended to use with the Biomerieux miniVIDAS® analyzer and VIDAS® D-dimer assay to verify the calibration of the measuring range.	The Triage® D-dimer Calibration Verification Controls are to be used with the Triage® D-dimer Test and Triage® MeterPlus to verify the calibration of the Triage® D-dimer test throughout the measurable range. The Triage® D-dimer Calibration Verification Controls are assayed materials to be used with the Triage® D-dimer Test and Triage® MeterPlus to assist the laboratory in monitoring test performance.
Number of levels per set	5	Same
Matrix	Human based plasma	Same

Differences		
Item		
Matrix	Lyophilized	Liquid
Closed vial stability	2-8°C for 24 months	-20°C for 9 months
Open vial stability	2 days when stored at 2-8°C	1 day when stored at 2-8°C

K. Standard/Guidance Document Referenced (if applicable):

CLSI EP06-A: Evaluation of Linearity of Quantitative Measurement Procedures: A Statistical Approach.

L. Test Principle:

The Audit™ MicroCV™ D-Dimer Linearity Set is used to verify the calibration of the D-dimer measuring range of the miniVIDAS® analyzer.

M. Performance Characteristics:

1. Analytical performance:
 - a. *Precision/Reproducibility:*

For each level of D-Dimer Linearity Set, 15 replicates were tested on the miniVIDAS[®] on three lots. All levels resulted <10% CV.

- b. *Linearity/assay reportable range:*
Linearity was determined using three lots of the D-Dimer Linearity Set. The mean D-dimer concentration of each of the 5 levels was plotted vs. five assigned levels of concentration. A linear regression value was obtained for each lot, and all results were within the limit of acceptance $r^2 > 0.95$.
 - c. *Traceability, Stability, Expected values (controls, calibrators, or methods):*
 - Traceability: All reagent components are obtained from commercial vendors.
 - Open vial stability: A 2-day open vial stability claim was verified using three lots of the Audit[™] MicroCV[™] D-Dimer Linearity Set. All 5 levels were tested on day zero and day 2. The percent recovery is determined in comparison to day zero values. The percent recovery is within $\pm 10\%$ limit of acceptance.
 - Closed vial stability: An accelerated stability is used to predict shelf life. The vials are stressed at 25°C for 64 days to predict two-year stability when stored at 2-8°C. The percent recovery of all levels is determined in comparison to day zero values and the product is considered stable when the recovered values are within $\pm 10\%$. Real time studies are ongoing to support the shelf life of the product.
 - Value assignment: For each level of D-Dimer Linearity Set, 15 separate vials were tested on one miniVIDAS[®] analyzer yielding 15 measurements. The mean of each level was used to calculate the target concentration. The target range of each level was calculated as $\pm 1SD$ of the target concentration.
 - d. *Detection limit:*
Not applicable
 - e. *Analytical specificity:*
Not applicable
 - f. *Assay cut-off:*
Not applicable
2. Comparison studies:
 - a. *Method comparison with predicate device:*
Not applicable
 - b. *Matrix comparison:*
Not applicable
3. Clinical studies:
 - a. *Clinical Sensitivity:*
Not applicable
 - b. *Clinical specificity:*
Not applicable
 - c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable
4. Clinical cut-off:
Not applicable

5. Expected values/Reference range:

The mean and expected assay range for each level are provided in the labeling.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.